Heading to the 28th ECCMID( European Congress of Clinical Microbiology and Infectious Diseases) in Madrid, Spain, from April 21 - 24, 2018. MGI and Curetis can be found at booth #79, hall 10, during the conference.
At the conference, Curetis will introduce its new Unyvero UTI Application Cartridge for the rapid syndromic testing of urinary tract infections for which the Company expects to receive CE-IVD mark in the near-term. Unyvero UTI will complement Curetis' portfolio of rapid molecular microbiology tests for severe infections in hospitalized patients, which includes CE-IVD applications for pneumonia (HPN), implant and tissue infections (ITI), bloodstream infections (BCU), intra-abdominal infections (IAI) and the recently U.S.-FDA cleared Unyvero LRT Application for lower respiratory tract infections for the U.S. market.
The Company will also provide an update on its Unyvero A30 RQ Analyzer and its first A30 RQ Application Cartridge, which are in development for expected CE-IVD marking in 2019. The A30 RQ Analyzer for low- to mid-plex testing will complement the current Unyvero A50 Analyzer for high-plex syndromic testing and expand the Unyvero Platform to a modular and flexible 'any-plex' package for rapid diagnostics in molecular microbiology.
Together with its partner MGI Tech Co. Ltd (MGI), Shenzhen, China, Curetis will showcase its concept for a next-generation molecular microbiology package for the automated detection of microbial pathogens and genetic markers for antibiotic resistances using next generation sequencing (NGS) technology. The novel sample-to-answer package in development is building on MGI's recently launched MGIFLP NGS workstation, combined with Curetis' sample preparation technology and Ares Genetics' AMR data analytics technologies. Representatives of MGI will be present at the Curetis booth to discuss the partnership and the in-development package.
Curetis N.V.'s (Euronext: CURE) goal is to become a leading provider of innovative solutions for molecular microbiology diagnostics designed to address the global challenge of diagnosing severe infectious diseases and identifying antibiotic resistances in hospitalized patients.
Curetis' Unyvero System is a versatile, fast and highly automated molecular diagnostic platform for easy-to-use, cartridge-based solutions for the comprehensive and rapid detection of pathogens and antimicrobial resistance markers in a range of severe infectious disease indications. Results are available within hours, a process that can take days or even weeks if performed with standard diagnostic procedures, and thereby facilitates improved patient outcomes, stringent antibiotic stewardship and health economic benefits. Unyvero in vitro diagnostic (IVD) products are marketed in Europe, the Middle East, Asia and the U.S.
Curetis' wholly owned subsidiary Ares Genetics GmbH offers next-generation solutions for infectious disease diagnostics and therapeutics. The ARES Technology Platform combines the world’s most comprehensive database on the genetics of antimicrobial resistances, ARESdb, with advanced bioinformatics and artificial intelligence.
For further information, please visit www.curetis.com and www.ares-genetics.com.